Economic and National Security Threats Create Lithium Bonanza
The U.S. and China are fighting for new sources of lithium – the linchpin of clean energy. Lithium mining operations have been declared a national emergency. Biden has ordered America's lithium supply chain to be strengthened and investors in lithium exploration companies are rejoicing. We may be entering a decades-long lithium bull run. You don't want to miss it.
Click here for the full story.
Ling Zeng, insider at Dicerna Pharmaceuticals
Ling Zeng Insider Alerts

Get notified the next time Ling Zeng buys or sells Dicerna Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Ling Zeng Insider Information

Ling Zeng, J.D., joined Dicerna as Chief Legal Officer and Secretary in September 2020. She brings to her role more than 20 years of broad and deep experience in biopharmaceutical law and global drug development and has held multiple leadership positions in North America, Europe and the Asia-Pacific region.

Ms. Zeng joined Dicerna from Novartis AG where she served as Deputy Head of the Legal M&A Group responsible for mergers and acquisitions (M&A). Prior to Novartis, Ms. Zeng held several senior-level positions at Bausch Health Companies, Inc., most recently as Vice President and General Counsel for Europe, the Middle East and Africa (EMEA), where she was responsible for EMEA legal matters in over 30 countries, and provided counsel on business development efforts, commercial operations, compliance, regulatory and IP strategies, and M&A transactions and integrations. Earlier in her career, Ms. Zeng was an associate at Cleary, Gottlieb, Steen & Hamilton in New York. Ms. Zeng was a Research Scientist prior to beginning her legal career.

Ms. Zeng earned her Juris Doctor, cum laude, from Georgetown University, a Master of Science degree in biophysics from Brandeis University, and a Bachelor of Science degree in physics from Peking University.

How do I contact Ling Zeng?

The corporate mailing address for Ms. Zeng and other Dicerna Pharmaceuticals executives is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. Dicerna Pharmaceuticals can also be reached via phone at (617) 621-8097 and via email at [email protected]

Has Ling Zeng been buying or selling shares of Dicerna Pharmaceuticals?

Ling Zeng has not been actively trading shares of Dicerna Pharmaceuticals during the past quarter. Most recently, Ling Zeng sold 1,334 shares of the business's stock in a transaction on Friday, September 17th. The shares were sold at an average price of $21.47, for a transaction totalling $28,640.98.

Who are Dicerna Pharmaceuticals' active insiders?

Dicerna Pharmaceuticals' insider roster includes Shreeram Aradhye (EVP), Bob Brown (EVP), Robert Ciappenelli (Insider), Douglas Fambrough (CEO), Marc Kozin (Director), Regina Paglia (Insider), James Weissman (COO), and Ling Zeng (Insider).

Are insiders buying or selling shares of Dicerna Pharmaceuticals?

In the last year, Dicerna Pharmaceuticals insiders bought shares 2 times. They purchased a total of 8,000 shares worth more than $181,480.00. In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 1,277,035 shares worth more than $32,649,559.26. The most recent insider tranaction occured on November, 18th when EVP Bob D Brown sold 24,936 shares worth more than $946,071.84. Insiders at Dicerna Pharmaceuticals own 10.2 % of the company.

Information on this page was last updated on 11/18/2021.

Ling Zeng Insider Trading History at Dicerna Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/17/2021Sell1,334$21.47$28,640.98View SEC Filing Icon  
See Full Table

Ling Zeng Buying and Selling Activity at Dicerna Pharmaceuticals

This chart shows Ling Zeng's buying and selling at Dicerna Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dicerna Pharmaceuticals Company Overview

Dicerna Pharmaceuticals logo
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $38.08
Low: $37.96
High: $38.13

50 Day Range

MA: $23.73
Low: $19.26
High: $38.08

2 Week Range

Now: $38.08
Low: $19.06
High: $40.14


10,487,528 shs

Average Volume

4,377,718 shs

Market Capitalization

$2.98 billion

P/E Ratio


Dividend Yield



Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock